Click here to close now.




















Welcome!

News Feed Item

EntreMed Reports 2013 Fourth Quarter And Full Year Financial Results

ROCKVILLE, Md., March 21, 2014 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, today reported financial results for the three and 12 months ended December 31, 2013. 

EntreMed logo

The Company reported a net loss of ($1.3 million), or ($0.05) per share for the three months ended December 31, 2013.  This compares with net loss of ($0.4 million), or ($0.02) per share for the fourth quarter of 2012.  The increase in net loss primarily was due to the expected decline in Celgene Corporation's sales of Thalomid® in 2013 which resulted in no recorded revenue from royalties for the Company in the fourth quarter of 2013, compared to $0.7 million royalty revenue earned in 2012.

The net loss for 2013 was ($5.7) million or ($0.22) per share, compared with a net loss of ($14.5) million or ($0.78) per share for 2012. The reported net loss for 2012 included non-cash interest charges of $10.0 million associated with the Company's 2012 financing, recorded in accordance with U.S. Generally Accepted Accounting Principles. Excluding these charges, the net loss for 2012 was ($4.5) million or ($0.25) per share.

As of December 31, 2013, EntreMed had cash and cash equivalents of $15.1 million

Sara B. Capitelli, EntreMed's Vice President, Finance and Principal Accounting Officer, commented, "Our research and development expenses for the fourth quarter increased over the prior year due to costs of clinical trials that began in 2013, along with higher personnel and other clinical development costs of ENMD-2076 in China during 2013.  We are continuing to execute our clinical development plans in the U.S. and China, and expect operating expenses to increase in 2014.  Whereas we recorded royalty revenue of $0.7 million in 2012, there were no royalty revenues from Celgene's sales of Thalomid® in 2013, which was in line with our expectations and reflects a decline in sales of Thalomid® in the United States." 

Further information regarding the Company, including its Annual Report on Form 10-K for the year ended December 31, 2013, can be found at www.entremed.com.

Dr. Ken Ren, Chief Executive Officer, commented, "Our financial results for the quarter and year ended December 31, 2013 are largely as expected.  We continue to manage our operating costs prudently while we advance our trials with ENMD-2076 for a number of cancers in North America and China, and make progress on identifying new compounds to license, particularly for the rapidly growing pharmaceutical market in China."

Dr. Ren continued, "We are pleased to have achieved a number of milestones in 2013 and recent weeks.  In particular, we strengthened our intellectual property with the issuance in China of a patent covering composition of matter and uses to treat a number of cancers for our lead compound, ENMD-2076.  This type of patent is one of the strongest patents one can achieve in China.  In mid-2013, we filed a new global import drug clinical trial application with China's Food and Drug Administration (CFDA) for ENMD-2076 for the treatment of advanced/metastatic sarcomas.  We ended the year with the initiation of a Phase 2 trial for EMND-2076 in ovarian clear cell carcinomas at the Princess Margaret Cancer center in Toronto, and followed in early 2014 with the submission of a global import drug clinical trial application with the CFDA for the same indication."

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action.  ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase.  Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers.  ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases, which have been shown to play important roles in the pathology of several cancers.  ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers including ovarian, breast, liver, renal and sarcoma, as well as in leukemia and multiple myeloma.  EntreMed is completing a Phase 2 trial of ENMD-2076 in ovarian cancer.  In addition, EntreMed is conducting a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer, a Phase 2 study in advanced/metastatic soft tissue sarcoma, and a Phase 2 study in advanced ovarian clear cell carcinomas. ENMD-2076 has received orphan drug designation from the U.S. FDA for the treatment of ovarian cancer, multiple myeloma and acute myeloid leukemia.

About EntreMed

EntreMed is a clinical-stage pharmaceutical company employing a drug-development strategy that leverages resources in both North America and in China to develop therapeutics for the treatment of cancer and other diseases.  Its lead compound, ENMD-2076, a selective angiogenic kinase inhibitor, has completed several Phase 1 studies in solid tumors, multiple myeloma and leukemia, and is completing a multi-center Phase 2 study in ovarian cancer.  EntreMed is conducting a Phase 2 study of ENMD-2076 in triple-negative breast cancer, a Phase 2 study of ENMD-2076 in advanced/metastatic soft tissue sarcoma, and a Phase 2 study of ENMD-2076 in advanced ovarian clear cell carcinomas.  The Company is headquartered in Rockville, Maryland and has a wholly owned subsidiary in Beijing, China.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the U.S. Securities and Exchange Commission.

Forward Looking Statements           

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals.  Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; the difficulty of executing our business strategy in China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidate or future candidates; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; risks associated with our product candidates; risks associated with any early-stage products under development; the risk that results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; and risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).  Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition.  We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

COMPANY CONTACT:
EntreMed, Inc.
240.864.2643
[email protected]

INVESTOR CONTACT:
LHA
Kim Sutton Golodetz
212.838.3777
[email protected]


(Financial Table Follows)



ENTREMED, INC.

SUMMARY OF OPERATING RESULTS

 

Three Months Ended

December 31,



2013

2012




Total revenues

$                -

$    669,310




Research and development

$    612,634

$    494,712




General and administrative

$    696,251

$   535,096




Net loss

$ (1,308,468)

$  (360,430)




Net loss per share attributable to

common shareholders (basic and diluted)

$        (0.05)

$       (0.02)




Weighted average number of

shares outstanding (basic and diluted)

27,040,429

22,503,393


12 Months Ended

December 31,



2013

2012




Total revenues

$                   -

$      669,310




Research and development

$    2,749,430

$   2,375,339




General and administrative

$   2,990,589

$   2,797,971




Interest (income) expense, net

$        (1,658)

$10,041,224




Net loss

$ (5,738,361)

$ (14,545,224)




Dividend on Series A convertible preferred stock

$                  -

$    (335,000)




Net loss attributable to common shareholders

$ (5,738,361)

$ (14,880,224)




Net loss per share attributable to

common shareholders (basic and diluted)

$         (0.22)

$         (0.78)




Weighted average number of

shares outstanding (basic and diluted)

26,125,852

19,055,064




Cash and Cash Equivalents

$ 15,131,671

$  8,049,237

 

Logo - http://photos.prnewswire.com/prnh/20010620/ENMDLOGO

SOURCE EntreMed, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Red Hat is investing in Tesora, the number one contributor to OpenStack Trove Database as a Service (DBaaS) also ranked among the top 20 companies contributing to OpenStack overall. Tesora, the company bringing OpenStack Trove Database as a Service (DBaaS) to the enterprise, has announced that Red Hat and others have invested in the company as a part of Tesora's latest funding round. The funding agreement expands on the ongoing collaboration between Tesora and Red Hat, which dates back to Febr...
As more and more data is generated from a variety of connected devices, the need to get insights from this data and predict future behavior and trends is increasingly essential for businesses. Real-time stream processing is needed in a variety of different industries such as Manufacturing, Oil and Gas, Automobile, Finance, Online Retail, Smart Grids, and Healthcare. Azure Stream Analytics is a fully managed distributed stream computation service that provides low latency, scalable processing of ...
Too often with compelling new technologies market participants become overly enamored with that attractiveness of the technology and neglect underlying business drivers. This tendency, what some call the “newest shiny object syndrome,” is understandable given that virtually all of us are heavily engaged in technology. But it is also mistaken. Without concrete business cases driving its deployment, IoT, like many other technologies before it, will fade into obscurity.
Puppet Labs has announced the next major update to its flagship product: Puppet Enterprise 2015.2. This release includes new features providing DevOps teams with clarity, simplicity and additional management capabilities, including an all-new user interface, an interactive graph for visualizing infrastructure code, a new unified agent and broader infrastructure support.
With the proliferation of connected devices underpinning new Internet of Things systems, Brandon Schulz, Director of Luxoft IoT – Retail, will be looking at the transformation of the retail customer experience in brick and mortar stores in his session at @ThingsExpo. Questions he will address include: Will beacons drop to the wayside like QR codes, or be a proximity-based profit driver? How will the customer experience change in stores of all types when everything can be instrumented and a...
Consumer IoT applications provide data about the user that just doesn’t exist in traditional PC or mobile web applications. This rich data, or “context,” enables the highly personalized consumer experiences that characterize many consumer IoT apps. This same data is also providing brands with unprecedented insight into how their connected products are being used, while, at the same time, powering highly targeted engagement and marketing opportunities. In his session at @ThingsExpo, Nathan Trel...
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
Cloud and datacenter migration innovator AppZero has joined the Microsoft Enterprise Cloud Alliance Program. AppZero is a fast, flexible way to move Windows Server applications from any source machine – physical or virtual – to any destination server, in any cloud or datacenter, using its patented container technology. AppZero’s container is also called a Virtual Application Appliance (VAA). To facilitate Microsoft Azure onboarding, AppZero has two purpose-built offerings: AppZero SP for Azure,...
WSM International, the pioneer and leader in server migration services, has announced an agreement with WHOA.com, a leader in providing secure public, private and hybrid cloud computing services. Under terms of the agreement, WSM will provide migration services to WHOA.com customers to relocate some or all of their applications, digital assets, and other computing workloads to WHOA.com enterprise-class, secure cloud infrastructure. The migration services include detailed evaluation and planning...
SYS-CON Events announced today that G2G3 will exhibit at SYS-CON's @DevOpsSummit Silicon Valley, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Based on a collective appreciation for user experience, design, and technology, G2G3 is uniquely qualified and motivated to redefine how organizations and people engage in an increasingly digital world.
A producer of the first smartphones and tablets, presenter Lee M. Williams will talk about how he is now applying his experience in mobile technology to the design and development of the next generation of Environmental and Sustainability Services at ETwater. In his session at @ThingsExpo, Lee Williams, COO of ETwater, will talk about how he is now applying his experience in mobile technology to the design and development of the next generation of Environmental and Sustainability Services at ET...
SYS-CON Events announced today the Containers & Microservices Bootcamp, being held November 3-4, 2015, in conjunction with 17th Cloud Expo, @ThingsExpo, and @DevOpsSummit at the Santa Clara Convention Center in Santa Clara, CA. This is your chance to get started with the latest technology in the industry. Combined with real-world scenarios and use cases, the Containers and Microservices Bootcamp, led by Janakiram MSV, a Microsoft Regional Director, will include presentations as well as hands-on...
SYS-CON Events announced today that Micron Technology, Inc., a global leader in advanced semiconductor systems, will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Micron’s broad portfolio of high-performance memory technologies – including DRAM, NAND and NOR Flash – is the basis for solid state drives, modules, multichip packages and other system solutions. Backed by more than 35 years of tech...
This Enterprise Strategy Group lab validation report of the NEC Express5800/R320 server with Intel® Xeon® processor presents the benefits of 99.999% uptime NEC fault-tolerant servers that lower overall virtualized server total cost of ownership. This report also includes survey data on the significant costs associated with system outages impacting enterprise and web applications. Click Here to Download Report Now!
SYS-CON Events announced today that Pythian, a global IT services company specializing in helping companies leverage disruptive technologies to optimize revenue-generating systems, has been named “Bronze Sponsor” of SYS-CON's 17th Cloud Expo, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Founded in 1997, Pythian is a global IT services company that helps companies compete by adopting disruptive technologies such as cloud, Big Data, advance...